Sutro Biopharma is undergoing a seismic shake-up—jettisoning its CEO, half of its workforce, its lead candidate and its manufacturing facility in a major bid to save cash. The almost 50% layoffs ...

Jane Chung has replaced Bill Newell as Sutro's CEO. Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its attention to a trio of ...

Sutro Biopharma Inc (NASDAQ:STRO) has prioritized three wholly owned pre-clinical programs in its next-generation ADC pipeline, indicating a focused strategic direction. The company's cash runway ...

Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The company had revenue of $14.00 million for the quarter, compared to the consensus estimate of $10 ...

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.

Sutro Biopharma , Inc. (NASDAQ:STRO), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs), has recently undergone a significant transformation in its ...

NASDAQ:STRO opened at $0.81 on Friday. Sutro Biopharma has a 12 month low of $0.81 and a 12 month high of $6.13. The firm has a market capitalization of $66.80 million, a PE ratio of -0.50 and a ...

Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its dual-payload ADC programs, while deprioritizing development of luveltamab ...

Sutro Biopharma (NASDAQ:STRO) fell ~14% in the premarket on Friday after the company announced its decision to deprioritize its studies into the antibody-drug conjugate luveltamab tazevibulin as ...

On Monday, H.C. Wainwright analysts revised their stance on Sutro Biopharma (NASDAQ: NASDAQ:STRO), downgrading the stock from "Buy" to "Neutral." Alongside this change, they significantly lowered ...

Oppenheimer analyst Jay Olson downgraded Sutro Biopharma (STRO) to Perform from Outperform after the company reported Q4 results and announced restructuring plans. The firm is “not too surprised ...